Beta thalassemia minor: a potential risk factor for osteopenia and osteoporosis

Felicia Woron , Thea Anderson , Catriona Hong , Parvathy Madhavan

Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (5) : 213 -7.

PDF (1582KB)
Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (5) :213 -7. DOI: 10.37349/eemd.2024.00017
Case Report
research-article
Beta thalassemia minor: a potential risk factor for osteopenia and osteoporosis
Author information +
History +
PDF (1582KB)

Abstract

A 74-year-old male patient with beta thalassemia minor presented in 2022 for a follow-up of osteoporosis diagnosed prior to 2004. At the time of presentation, his medical history included: radiation exposure to his head and neck, goiter, prostate cancer status post resection in 2019 without a history of anti-androgen therapy, and atrial fibrillation, for which he had been prescribed apixaban since 2021. Treatment with risedronate occurred from approximately 2004 to about 2011, with improvement in bone density to osteopenia. He had also taken vitamin D and calcium supplementation and engaged in regular weight-bearing exercise. The patient had no other known risk factors for decreased bone mineral density preceding the onset of his osteoporosis, and a previous workup for secondary causes of his osteoporosis etiology proved negative. We propose that beta thalassemia minor is potentially a risk factor for osteopenia and osteoporosis, and that bisphosphonates can be considered for management when therapeutic intervention is indicated. Even in the absence of other known risk factors, clinicians should consider periodically screening beta thalassemia minor patients with DXA for evaluation of bone health.

Keywords

Osteoporosis / osteopenia / beta thalassemia / bone mineral density

Cite this article

Download citation ▾
Felicia Woron, Thea Anderson, Catriona Hong, Parvathy Madhavan. Beta thalassemia minor: a potential risk factor for osteopenia and osteoporosis. Exploration of Endocrine and Metabolic Diseases, 2024, 1 (5) : 213-7 DOI:10.37349/eemd.2024.00017

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Yavropoulou MP, Anastasilakis AD, Tzoulis P, Tournis S, Rigatou E, Kassi E, et al. Approach to the management of β thalassemia major associated osteoporosis-A long-standing relationship revisited. Acta Biomed. 2022; 93: e2022305.

[2]

Soliman A, Sanctis VD, Yassin M. Vitamin D status in thalassemia major: an update. Mediterr J Hematol Infect Dis. 2013; 5: e2013057.

[3]

Greep N, Anderson AL, Gallagher JC. Thalassemia minor: a risk factor for osteoporosis? Bone Miner. 1992; 16: 63-72.

[4]

Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, et al. Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol. 2012; 159: 462-71.

[5]

Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev. 2008; 6: 86-93.

[6]

Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A. Pathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical Experience. J Clin Res Pediatr Endocrinol. 2019; 11: 110-7.

[7]

Perisano C, Marzetti E, Spinelli MS, Callà CAM, Graci C, Maccauro G. Physiopathology of Bone Modifications in β-Thalassemia. Anemia. 2012; 2012: 320737.

[8]

Kalef-Ezra J, Challa A, Chaliasos N, Hatzikonstantinou I, Papaefstathiou I, Cholevas V, et al. Bone minerals in beta-thalassemia minor. Bone. 1995; 16: 651-5.

[9]

Woron F, Madhavan P. THU451 Low Bone Mineral Density In A Patient With Thalassemia Minor. J Endocr Soc. 2023; 7: bvad114.412.

[10]

Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013; 98: 833-44.

PDF (1582KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉